J3M-MC-JZQH

Medable Inc.

Google PlayNo ratingFreeFirst seen 25 Oct 2026

Compare Open in Google Play

Similar apps

Compare all

App info

Installs: 10+
Category: Medical
Content rating: Everyone
Version: 5.4.1100.1-prod
Released: Mar 13, 2025
Last updated: 4 Feb 2026
In-app purchases: No
Contains ads: No
Promo video: No
Requires Android: 8.0

—No ratings yet

5

0

4

0

3

0

2

0

1

0

Screenshots

Revenue

Estimate

Not enough data yet.

Google Play only. Downloads from daily Top free ranks (or the store's install count); in-app revenue from Top grossing ranks, calibrated on AppTweak's US estimates, or else from downloads; ads from public ad benchmarks. Not reported figures.

Rankings

This app isn't in any of our charts yet.

What's newin version 5.4.1100.1-prod

Bug fixes and performance improvements

About this app

Study for Participants with Resected or Unresectable KRAS G12C-Mutant, NSCLC

Read full description

This app has been exclusively created for participants with Resected or Unresectable KRAS G12C-Mutant, NSCLC. It contains Televisit functionality and allows participants to complete questionnaires. The study is a Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02. This app is specifically intended for participants in the J3M-MC-JZQH study only. (Televisit tasks are not enabled by default and may be enabled as needed, by study officials.)

support@medable.com

Revenue

Estimate

Not enough data yet.

Google Play only. Downloads from daily Top free ranks (or the store's install count); in-app revenue from Top grossing ranks, calibrated on AppTweak's US estimates, or else from downloads; ads from public ad benchmarks. Not reported figures.